BACKGROUND:Chronic inflammation and oxidative stress are common risk factors for atherosclerosis. Zinc is an essential micronutrient that can function as an antiinflammatory and antioxidative agent, and as such, it may have atheroprotective properties. OBJECTIVE: We hypothesized that zinc down-regulates the production of atherosclerosis-related cytokines/molecules in humans. DESIGN: To examine these effects, we conducted a randomized, double-blinded, placebo trial of zinc supplementation in elderly subjects. We recruited 40 healthy elderly subjects (aged 56-83 y) and randomly assigned them to 2 groups. One group was given an oral dose of 45 mg zinc/d as a gluconate for 6 mo. The other group was given a placebo. Cell culture models were conducted to study the mechanism of zinc as an atheroprotective agent. RESULTS: After 6 mo of supplementation, the intake of zinc, compared with intake of placebo, increased the concentrations of plasma zinc and decreased the concentrations of plasma high-sensitivity C-reactive protein (hsCRP), interleukin (IL)-6, macrophage chemoattractant protein 1 (MCP-1), vascular cell adhesion molecule 1 (VCAM-1), secretory phospholipase A2, and malondialdehyde and hydroxyalkenals (MDA+HAE) in elderly subjects. Regression analysis showed that changes in concentrations of plasma zinc were inversely associated with changes in concentrations of plasma hsCRP, MCP-1, VCAM-1, and MDA+HAE after 6 mo of supplementation. In cell culture studies, we showed that zinc decreased the generation of tumor necrosis factor-alpha, IL-1beta, VCAM-1, and MDA+HAE and the activation of nuclear transcription factor kappaB and increased antiinflammatory proteins A20 and peroxisome proliferator-activated receptor-alpha in human monocytic leukemia THP-1 cells and human aortic endothelial cells compared with zinc-deficient cells. CONCLUSION: These findings suggest that zinc may have a protective effect in atherosclerosis because of its antiinflammatory and antioxidant functions.
RCT Entities:
BACKGROUND: Chronic inflammation and oxidative stress are common risk factors for atherosclerosis. Zinc is an essential micronutrient that can function as an antiinflammatory and antioxidative agent, and as such, it may have atheroprotective properties. OBJECTIVE: We hypothesized that zinc down-regulates the production of atherosclerosis-related cytokines/molecules in humans. DESIGN: To examine these effects, we conducted a randomized, double-blinded, placebo trial of zinc supplementation in elderly subjects. We recruited 40 healthy elderly subjects (aged 56-83 y) and randomly assigned them to 2 groups. One group was given an oral dose of 45 mg zinc/d as a gluconate for 6 mo. The other group was given a placebo. Cell culture models were conducted to study the mechanism of zinc as an atheroprotective agent. RESULTS: After 6 mo of supplementation, the intake of zinc, compared with intake of placebo, increased the concentrations of plasma zinc and decreased the concentrations of plasma high-sensitivity C-reactive protein (hsCRP), interleukin (IL)-6, macrophage chemoattractant protein 1 (MCP-1), vascular cell adhesion molecule 1 (VCAM-1), secretory phospholipase A2, and malondialdehyde and hydroxyalkenals (MDA+HAE) in elderly subjects. Regression analysis showed that changes in concentrations of plasma zinc were inversely associated with changes in concentrations of plasma hsCRP, MCP-1, VCAM-1, and MDA+HAE after 6 mo of supplementation. In cell culture studies, we showed that zinc decreased the generation of tumor necrosis factor-alpha, IL-1beta, VCAM-1, and MDA+HAE and the activation of nuclear transcription factor kappaB and increased antiinflammatory proteins A20 and peroxisome proliferator-activated receptor-alpha in human monocytic leukemia THP-1 cells and human aortic endothelial cells compared with zinc-deficient cells. CONCLUSION: These findings suggest that zinc may have a protective effect in atherosclerosis because of its antiinflammatory and antioxidant functions.
Authors: Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor Journal: Circulation Date: 2003-01-28 Impact factor: 29.690
Authors: A Mazzone; C Cusa; I Mazzucchelli; M Vezzoli; E Ottini; S Ghio; G Tossini; R Pacifici; P Zuccaro Journal: Clin Chem Lab Med Date: 2001-09 Impact factor: 3.694
Authors: Daniel E Conway; Sungmun Lee; Suzanne G Eskin; Ankit K Shah; Hanjoong Jo; Larry V McIntire Journal: Am J Physiol Cell Physiol Date: 2010-09-22 Impact factor: 4.249
Authors: Luis Velázquez-Pérez; Jorge Rodríguez-Chanfrau; Julio Cesar García-Rodríguez; Gilberto Sánchez-Cruz; Raúl Aguilera-Rodríguez; Roberto Rodríguez-Labrada; Julio Cesar Rodríguez-Díaz; Nalia Canales-Ochoa; Dennis Almaguer Gotay; Luis E Almaguer Mederos; José M Laffita Mesa; Marlene Porto-Verdecia; Consuelo González Triana; Noemí Rodríguez Pupo; Idania Hidalgo Batista; Orestes D López-Hernandez; Iverlis Díaz Polanco; Arelis Jayme Novas Journal: Neurochem Res Date: 2011-05-12 Impact factor: 3.996
Authors: Robertina Giacconi; Andreas Simm; Alexander Navarrete Santos; Laura Costarelli; Marco Malavolta; Patrizia Mecocci; Francesco Piacenza; Andrea Basso; Tamas Fulop; Lothar Rink; George Dedoussis; Stavroula Kanoni; Georges Herbein; Jolanta Jajte; Eugenio Mocchegiani Journal: Genes Nutr Date: 2014-08-23 Impact factor: 5.523
Authors: Siarhei Slinko; Giovanna Piraino; Paul W Hake; John R Ledford; Michael O'Connor; Patrick Lahni; Patrick D Solan; Hector R Wong; Basilia Zingarelli Journal: Shock Date: 2014-04 Impact factor: 3.454